Prevalence and Risk Factors of Alzheimerﹸs Disease in Elderly People, Kerman, Iran: A House Based Survey

Document Type : Original Article


1 Neurology Research Center & Department of Neurology, Shafa Hospital, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

2 Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran Department of Traditional medicine, Faculty of Persian medicine, Kerman University of Medical Sciences, Kerman, Iran

3 Department of Scientometrics, Kerman University of Medical Sciences, Kerman, Iran

4 Department of Traditional medicine, Faculty of Persian medicine, Kerman University of Medical Sciences, Kerman, Iran Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran


Background: Population aging is occurring in almost every country in the world, resulting in reduced mortality, reduced fertility, and increased life expectancy. With an increase in the elderly population, chronic diseases related to aging, including Alzheimer's disease will also increase, which is a big problem for the health in society. Since early diagnosis can help a more effective treatment, this study was conducted to determine the prevalence of Alzheimer's disease and its risk factors in people aged 50 and above in Kerman, Iran.
Methods: For sampling, a one-step random cluster method was used across 11 districts of Kerman for one year and a ten-item questionnaire provided by Alzheimer's World Association and MMSE was employed for data collection.
Results: A total of 4,191 people were surveyed, of which 1,213 were 50 years of age or older. 1111 people had disorder at least one question in the MMSE ten-item questionnaire. 26 of these people were diagnosed with Alzheimer's disease after further investigation.
Conclusion: The prevalence of Alzheimer's disease in Kerman was similar to that in the rest of the world. Many of the cases were over 80 years old and had serious illnesses. If they had been diagnosed in the early stages of the disease, their disease could be managed at a lower cost and more effectively.


  1. Bloom DE, Boersch-Supan A, McGee P, Seike A. Population aging: facts, challenges, and responses. [cited 2020 May 20] Available from:
  2. Lunenfeld B, Stratton P. The clinical consequences of an ageing world and preventive strategies. Best Pract Res Clin Obstet Gynaecol 2013; 27(5):643-59.
  3. Prince MJ, Wu F, Guo Y, Robledo LMG, O'Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. The Lancet. 2015; 385(9967):549-62.
  4. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res 2012; 43(8):600-8.
  5. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3):137-52.
  6. Soltanzadeh A. Neurologic Diseases. Tehran: Jafari; 2002. [In Persian].
  7. Ramshini H, Kosari N, Saeidian S. Inhibition of Amyloid Fibrils Formation from Hen Egg White Lysozyme by Satureia Hortensis Extract and its Effect on Learning and Spatial Memory of Rats. Journal of Kerman University of Medical Sciences. 2016;23(3):271-85.
  8. Morewitz SJ, Goldstein ML. Aging and Chronic Disorders. New York: Springer Science+Business Media; 2007. p. 28-34.
  9. Iranmanesh F, Shafiee K, Farzan A. The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial. Journal of Kerman University ofMedical Sciences, 2020; 27 (2): 113-119.
  10. United Nations. World Population Ageing 2013. New York: UN; 2013.
  11. Alzheimer’s Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 2015; 11(3):332-84.
  12. 2020 Alzheimer's disease Facts and Figures. The Journal of Alzheimers Association 2020; 16(3):391-460.
  13. Geldmacher DS. Differential diagnosis of dementia syndromes. Clin Geriatr Med 2004; 20(1):27-43.
  14. Katzman R. Editorial: the prevalence and malignancy of alzheimer disease. a major killer. Arch Neurol 1976; 33(4):217-8.
  15. Iranmanesh F, Sayyadi A, Fayegh A, Shafiee Z. Surveying of estrogen and progesterone effects on electroencephalogram and mini-mental status examination (MMSE) in female patients with Alzheimer’s disease. Journal of Birjand University of Medical Sciences 2006; 13(2):9-15. [In Persian].
  16. Prince M, Livingston G, Katona C. Mental health care for the elderly in low-income countries: a health systems approach. World Psychiatry 2007; 6(1):5-13.
  17. Harper S. Economic and social implications of aging societies. Science 2014; 346(6209):587-91.
  18. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008; 451(7179):716-9.
  19. United Nations. World Population Ageing 2002. New York: UN; 2002.
  20. Parsa NZ, Gaidano G, Mukherjee AB, Hauptschein RS, Lenoir G, Dalla-Favera R, et al. Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. Genes Chromosomes Cancer 1994; 9(1):13-8.
  21. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010; 75(1):35-41.
  22. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360(22):2302-9.
  23. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29(1-2):125-32.
  24. Agronin ME. Alzheimer Disease and Other Dementias: A Practical Guide. 2nd ed. USA: Lippincott Williams & Wilkins; 2007.
  25. Rezakhani S, Sedighi B, Pardakhty A, Shafiee K. Effects of Boswellia serrata on Improvement of Memory Impairment in Patients with Mild Cognitive Impairment: A Double-blind, Randomized, Placebo-controlled Study. Journal of Kerman University of Medical Sciences, 2020; 27 (4): 348-355.
  26. Rowland LP, Pedley TA, Merritt HH. Merritt's Neurology. 10th ed. USA: Lippincott Williams & Wilkins; 2000.
  27. Aminoff MJ, Josephson SA. Aminoff's Neurology and General Medicine. 5th ed. USA: Academic Press; 2014.
  28. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18(4):351-7.
  29. Kvitting AS, Fällman K, Wressle E, Marcusson J. Age‐normative MMSE data for older persons aged 85 to 93 in a Longitudinal Swedish Cohort. J Am Geriatr Soc 2019; 67(3):534-8.
  30. Morowatisharifabad MA, Fallah Z, Bidaki R, Hashemian Z, Fallahzadeh H, Rafatifard M, et al. The prevalence of Alzheimer’s disease preventive behaviors in elderly people, Yazd, Iran. Elderly Health Journal 2017; 3(1):16-22.
  31. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 2007; 28(11):1689-99.
  32. Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol 2002; 59(10):1589-93.
  33. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64(1):93-6.
  34. Rönnemaa E, Zethelius B, Sundelöf J, Sundström J, Degerman-Gunnarsson M, Berne C, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71(14):1065-71.
  35. Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O’Hara R, Ashford JW, et al. Active cigarette smoking in cognitively-normal elders and probable Alzheimer’s disease is associated with elevated cerebrospinal fluid oxidative stress biomarkers. J Alzheimers Dis 2016; 54(1):99-107.
  36. Toda N, Okamura T. Cigarette smoking impairs nitric oxide-mediated cerebral blood flow increase: Implications for Alzheimer's disease. J Pharmacol Sci 2016; 131(4):223-32.
  37. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016; 18(5):421-30.
  38. Chua XY, Choo RW, Ha NH, Cheong CY, Wee SL, Yap PL. Mapping modified Mini-Mental State Examination (MMSE) scores to dementia stages in a multi-ethnic Asian population. Int Psychogeriatr 2019; 31(1):147-51.
  39. Ansari NN, Naghdi S, Hasson S, Valizadeh L, Jalaie S. Validation of a Mini-Mental State Examination (MMSE) for the Persian population: a pilot study. Appl Neuropsychol 2010; 17(3):190-5.
  40. Galea M, Woodward M. Mini-mental state examination (MMSE). Aust J Physiother 2005; 51(3):198.
  41. Nourhashémi F, Gillette-Guyonnet S, Andrieu S, Ghisolfi A, Ousset PJ, Grandjean H, et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000; 71(2):643S-9S.
  42. Tajadini H, Choopani R, Saifadini R. Lifestyle methods for prevention of alzheimer’s disease from the perspective of traditional Persian medicine. J Evid Based Complementary Altern Med 2016; 21(3):243-5.
  43. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(8):a006239.
  44. Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci 2016; 18(4):437-46.
  45. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262(18):2551-6.
  46. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2):111-28.
  47. Shrestha LB. Population aging in developing countries. Health Aff (Millwood) 2000; 19(3):204-12.
  48. Alzheimer's Association. 2018 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2018; 14(3):367-429.
  49. Gholamzadeh S, Heshmati B, Mani A, Petramfar P, Baghery Z. The prevalence of Alzheimer’s disease; its risk and protective factors among the elderly population in Iran. Shiraz E-Medical Journal 2017; 18(9).
  50. Aajami Z, Kebriaeezadeh A, Nikfar S. Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran. Iran J Neurol 2019; 18(1):7-12.
  51. Guerreiro R, Bras J. The age factor in Alzheimer’s disease. Genome Med 2015; 7:106.
  52. Xue H, Sun Q, Liu L, Zhou L, Liang R, He R, et al. Risk factors of transition from mild cognitive impairment to Alzheimer's disease and death: a cohort study. Compr Psychiatry 2017; 78:91-7.
  53. Laws KR, Irvine K, Gale TM. Sex differences in Alzheimer's disease. Curr Opin Psychiatry 2018; 31(2):133-9.
  54. Abner EL, Nelson PT, Kryscio RJ, Schmitt FA, Fardo DW, Woltjer RL, et al. Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement 2016; 12(8):882-9.
  55. Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Lowe VJ, Graff‐Radford J, et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol 2017; 82(5):706-18.
  56. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2015; 11(6):710-7.
  57. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on family history of Alzheimer’s disease. Transl Psychiatry 2018; 8(1):99.